UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program
The UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program is a collaboration between the University of North Carolina at Chapel Hill and Duke University. The overarching goal of this two-year program is to cultivate a new generation of translational scientists equipped to address critical problems in clinical pharmacology. Trainees, guided by individualized development plans and mentoring teams, complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research in preparation for successful academic, regulatory or industrial careers as leaders and mentors to future generations of clinical pharmacologists. Four focus areas form the core of this training program:
- Drug Disposition and Action
- Quantitative Pharmacology/Pharmacometrics & Clinical Trial Design
- Individualized Therapy
- Drug-induced Organ Toxicity
Unique features of this training program include a focus on precision dosing and understudied areas in clinical pharmacology, specifically, pediatrics [including collaboration with the Pediatric Trials Network] and drug safety [UNC Institute for Drug Safety Sciences]. This program is supported by The National Institute of General Medical Sciences (NIGMS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) under award number T32 GM086330. This program is accredited by the American Board of Clinical Pharmacology (ABCP).